A Phase 2 clinical trial is set to launch in the UK to investigate dapansutrile (DAPA-PD), an anti-inflammatory drug, as a potential treatment to slow the progression of Parkinson's disease. The trial, funded in part by the Big Give Christmas Challenge, will involve 36 individuals with Parkinson's over a 12-month period.
The study, DAPA-PD, is designed to determine whether dapansutrile, an anti-inflammatory drug, can indeed slow the progression of Parkinson's. Parkinson's disease is a progressive neurodegenerative disorder affecting millions worldwide. Current treatments primarily manage symptoms, with no existing cure or therapies definitively proven to slow disease progression.
Trial Design and Objectives
The DAPA-PD trial will enroll 36 participants diagnosed with Parkinson's disease. Participants will be monitored over twelve months to assess the drug's impact on disease progression. The primary endpoint is to evaluate the safety and tolerability of dapansutrile in individuals with Parkinson's disease. Secondary endpoints will assess changes in motor and non-motor symptoms, as well as biomarkers associated with disease progression.
Funding and Support
Cure Parkinson's has been selected to participate in the Big Give's Christmas Challenge. From December 3rd to 10th, donations made to Cure Parkinson's through the Big Give website will be doubled. This initiative aims to raise £60,000 to support the dapansutrile trial.
Dapansutrile: A Potential New Hope
Dapansutrile represents a novel approach to treating Parkinson's by targeting inflammation, a key factor in the disease's progression. The trial could mark a significant step forward in the search for disease-modifying treatments.
